| |
|
The Investigational New Drug (IND) Program
The Investigational New Drug Program was established as part of the NCIC
Clinical Trials Group in 1982 as a result of two competing factors:
-
the high level of interest of Canadian investigators in exploring clinical
trials with new anti-cancer drugs, and
-
restricted access to such agents from the NCI
U.S., except to recognized cooperative groups.
Initially, funding was provided to support travel to Phase I and related
meetings, as well as for salary support for the medical onocologist director
(Dr. E. Eisenhauer) and secretary/data manager (J. Paquette). The initial
goal of the Program was to provide a support structure for access to information
necessary to launch a series of phase II trials in Canada. The Program
has since expanded somewhat beyond those initial goals, and is doing phase
I and II trials with cytotoxics and biologics. New agents, not only from
the NCI U.S. but also from the pharmaceutical industry, are studied.
The 1992 Site Review Team endorsed the expansion of the IND Program
to include more phase I trials and studies of biologic agents.
|
